Access challenges may undercut Novartis AG’s first-mover advantage as it seeks to establish itsnew plaque psoriasis treatment Cosentyx (secukinumab) in a tightly controlled reimbursement environment.
“The key going forward [for Cosentyx] is going to be gaining access, which we’re working through,” Novartis Pharmaceuticals Division Head David Epstein said during the company’s April 23 earnings call. “In the U.S